Ketamine therapy uses low-dose ketamine infusions or nasal spray (Spravato) to treat treatment-resistant depression, offering rapid relief when SSRIs fail, becoming widely available 2019-2023.

Medical Breakthrough

Ketamine, a dissociative anesthetic used since the 1960s, was discovered in the 2000s to have rapid-acting antidepressant effects. Unlike SSRIs requiring weeks to work, ketamine can alleviate suicidal ideation within hours.

FDA approved esketamine nasal spray (Spravato) in 2019 for treatment-resistant depression (TRD), marking the first new depression mechanism in decades (NMDA receptor antagonist vs. serotonin).

Treatment Landscape (2019-2023)

Ketamine clinics proliferated 2019-2023, offering:

• IV infusions ($400-800 per session, typically 6-session protocol)
• Nasal spray (Spravato, insurance-covered, clinic-administered)
• Lozenges (off-label, at-home use)
• IM injections (less common)

By 2023, hundreds of ketamine clinics operated in the US, though insurance coverage remained patchy outside Spravato.

Patient Experience

Sessions involve:

1. Screening (cardiac/psychiatric history)
2. Infusion (45-60 minutes, dissociative/psychedelic effects)
3. Recovery period (1-2 hours monitored)
4. Integration therapy (processing insights)

Patients report:

• “Floating” or “out of body” sensations
• Visual distortions, time dilation
• Emotional insights, perspective shifts
• Immediate mood lift (hours-days)

Efficacy & Limitations

Effectiveness:

• 50-70% response rate for treatment-resistant depression
• Rapid suicidal ideation relief (hours vs. weeks)
• Benefits beyond single session (though maintenance needed)

Concerns:

• Effects often temporary (maintenance infusions every 2-4 weeks)
• Abuse potential (recreational use history)
• Bladder damage with long-term use
• Dissociative experiences can be destabilizing
• Expensive, insurance barriers

Social Media Trends

Instagram/TikTok ketamine content 2020-2023:

• Patient testimonials (“saved my life”)
• Trip experience descriptions
• Clinic promotion (medical spa aesthetics)
• Criticism of commercialization/“K-hole therapy”
• Integration coaching offerings

Criticism

• Clinic proliferation without adequate psychiatric oversight
• Marketing to wealthy patients (accessibility issues)
• Overpromised as “cure” when maintenance often needed
• Recreational association stigma
• Lack of long-term safety data

Comparison to Psychedelics

Unlike MDMA/psilocybin (still in trials), ketamine is already legal for off-label depression use, making it the only legally accessible psychedelic-adjacent therapy. However, it lacks the FDA approval psychedelics are pursuing for specific indications.

Influential Voices

• Dr. Steven Levine (Ketamine clinic pioneer)
• Dr. John Krystal (Yale ketamine research since 1990s)
• Erica Zelfand (integrative medicine ketamine advocacy)

Related hashtags: #TreatmentResistantDepression #KetamineInfusion #Spravato #MentalHealthTreatment #PsychedelicTherapy